{"id":"W4321794008","doi":"10.1016/j.jtho.2023.02.003","title":"Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; BC Cancer Agency; Saskatchewan Cancer Agency; CancerCare Manitoba; Alberta Cancer Foundation; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; Canadian Cancer Society; University Health Network","funders":"EMD Serono; Merck Canada; Servier; Canadian Cancer Society; Ipsen; BeiGene; Les Laboratories Pierre Fabre; Astellas Pharma; Novocure; Eisai; Jazz Pharmaceuticals; Merck KGaA; Sanofi; GlaxoSmithKline; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Mesothelioma; Pemetrexed; Confidence interval; Internal medicine; Lung cancer; Interim analysis; Interim; Oncology; Clinical trial; Cancer; Chemotherapy; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001918995,0.0001815803,0.001712222,0.000707119,0.00004649218,0.000006790642,0.0001140374,0.00009089227,0.0002358241],"category_scores_gemma":[0.0007406813,0.0001156424,0.0002173231,0.0004411697,0.0001123621,0.000135259,0.00002971219,0.0002168023,0.000003663326],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005996639,"about_ca_system_score_gemma":0.0008227719,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005115549,"about_ca_topic_score_gemma":0.01170251,"domain_scores_codex":[0.9967064,0.0007075716,0.001537559,0.000204732,0.0005578343,0.0002859406],"domain_scores_gemma":[0.9974593,0.000417229,0.001451707,0.0001776106,0.0001583931,0.0003357646],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5835361,0.005000222,0.3599685,0.00008835585,0.0008115306,0.005177687,0.000924792,0.0003536696,0.0003774946,0.000006583245,0.000565268,0.04318981],"study_design_scores_gemma":[0.2802271,0.009275144,0.7067073,0.0002906794,0.001122537,0.0002333502,0.0009405069,0.00005627242,0.0001277454,0.00007272738,0.0008031514,0.0001435067],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971417,0.0002364773,0.000005264122,0.0006959194,0.0003523183,0.001342924,0.00008038184,0.000008290286,0.0001366982],"genre_scores_gemma":[0.9991481,0.00007483553,0.0001686734,0.0002107237,0.0001077058,0.00007393248,0.000059412,0.00002334244,0.0001332633],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3467388,"threshold_uncertainty_score":0.7733214,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02884808156540722,"score_gpt":0.4260797057055907,"score_spread":0.3972316241401834,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}